detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing watchman implantation: (target-watchman) a case–control study

The relation of device related thrombosis (drt) and major bleeding after left atrial appendage closure (laac) to laboratory thrombosis and hemostasis markers has not been studied. we performed a prospective case control study to identify clinical characteristics and laboratory markers in patients who developed drt and major bleeding following watchman laac. thromboelastography, platelet aggregation (pa), urinary 11-dehydrothromboxane b2 (utx), fibrinogen, d-dimer, thrombin time and von willebrand factor activity were determined at baseline, immediately following, and at 45 and 180 days post-laac (n = 32) and outcomes were followed for 1 year. baseline characteristics and thrombogenic profiles of patients with and without drt and/or barc bleeding were compared. mean age was 76 ± 8 years and chads2 vasc score was 4.4 ± 1.4. there were 3 drts (2 within 6 months, and 1 at 12 months), 4 type 3a barc bleeds, and 2 non-cardiac deaths. patients with drt had higher baseline thrombin-induced platelet–fibrin clot strength (68.0 ± 1.8 vs. 62.7 ± 4.7 mm, p = 0.06); fcs (35.6 ± 6.0 vs. 24.4 ± 6.6 mm, p = 0.009); and d-dimer (1712 ± 2330 vs. 283 ± 213 ng/ml, p = 0.001). at baseline, 5 patients had all 3 factors associated with high thrombotic risk and 2 experienced a drt within 6 months. patients with type 3a barc bleeding had lower baseline collagen-induced and 45-day adp-induced pa (p < 0.01 for both). drt following laac was associated with a baseline prothrombogenic profile whereas bleeding was associated with low platelet reactivity. these preliminary findings warrant further validation and have future implications on patient selection and adjunctive antithrombotic therapy following laac. clinical trial registration: https://clinicaltrials.gov/ct2/show/nct03040622.